Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective ...

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...

Add Yahoo as a preferred source to see more of our stories on Google. Antibody drug conjugates (ADCs) have gained significant momentum in recent years, due to their clinical successes in cancer ...

New therapies like T-cell engagers and antibody-drug conjugates are showing survival gains in pretreated small cell lung ...

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a ...

Over the past few years economic headwinds have resulted in fewer deals, with companies and private equity firms alike reassessing where to spend money. But one portion of the pharmaceutical industry ...

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...